SHANMUGAN SHANTHA: Open Payments
NPI 1255341798 · MANDEVILLE, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,568 in 87 payments from 12 companies in 2025. Trend: 2023 $847 · 2024 $2,265 · 2025 $1,568
Food & beverage: $1,568
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 13 | $244 |
| Janssen Pharmaceuticals, Inc | 9 | $244 |
| ABBVIE INC. | 13 | $169 |
| Neurocrine BioSciences, Inc. | 12 | $168 |
| Teva Pharmaceuticals USA, Inc. | 8 | $167 |
| Otsuka America Pharmaceutical, Inc. | 8 | $157 |
| E.R. Squibb & Sons, L.L.C. | 9 | $154 |
| Axsome Therapeutics, Inc. | 6 | $108 |
| Lundbeck LLC | 4 | $65 |
| Alkermes, Inc. | 2 | $39 |
Products named: CAPLYTA, INVEGA SUSTENNA, VRAYLAR, INGREZZA, COBENFY, UZEDY, REXULTI, Auvelity.
Industry payments across LA — which companies pay providers there.
